Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
274
169
153
361
348
110
Hasılat Artışı (YoY)
20%
10%
-57.99%
4%
216%
-13%
Satınalma Maliyeti
147
98
100
324
182
46
Brüt Kâr
127
71
52
36
165
63
Satış, Genel ve İdari
126
94
95
56
70
45
Araştırma ve Geliştirme
119
67
56
101
168
61
İşletme Giderleri
220
148
134
150
221
92
Diğer Finansman Gelirleri (Giderleri)
0
0
0
0
0
--
Kâr Öncesi Gelir
-115
-11
-98
-144
-69
-65
Kira Vergisi Gideri
4
0
2
-1
3
0
Net Kâr
-120
-12
-101
-143
-73
-64
Net Income Growth
Kâr Artışı
-806%
-88%
-28.99%
96%
14%
6,300%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
181.05
153.08
138.62
115.47
97.61
90.75
Hisse Değişimi (Yıllık Üst Üste)
28%
10%
20%
18%
8%
-1%
EPS (Diluted)
-0.66
-0.08
-0.73
-1.24
-0.75
-0.71
EPS Artışı
-650%
-89%
-41%
65%
6%
3,450%
Öz sermaye akışı
-17
-83
-217
-271
-16
118
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
46.35%
42.01%
33.98%
9.97%
47.41%
57.27%
Faaliyet Kâr Marjı
-33.57%
-45.56%
-53.59%
-31.3%
-15.8%
-25.45%
Kâr Marjı
-43.79%
-7.1%
-66.01%
-39.61%
-20.97%
-58.18%
Özsermaye Karlılık Oranı
-6.2%
-49.11%
-141.83%
-75.06%
-4.59%
107.27%
EBITDA
--
-58
-65
-92
-41
-19
EBITDA Marjinali
--
-34.31%
-42.48%
-25.48%
-11.78%
-17.27%
D&A EBITDA için
--
19
17
21
14
9
Faaliyet Kârı
-92
-77
-82
-113
-55
-28
Faaliyet Kâr Marjı
-33.57%
-45.56%
-53.59%
-31.3%
-15.8%
-25.45%
Verilen Vergi Oranı
-3.47%
0%
-2.04%
0.69%
-4.34%
0%
Önemli İstatistikler
Önceki Kapanış
$10.77
Açılış fiyatı
$10.84
Günün Aralığı
$10.74 - $11.28
52 haftalık aralık
$5.42 - $12.25
İşlem hacmi
5.3K
Ort.Hacim
18.8K
EPS (TTM)
-1.56
Dividend yield
--
Piyasa Değeri
$978.0M
Valneva SE nedir?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.